Riskpilot← Back to searchSign inGet full accessBILLEV PHARMA ApS
APSActiveCVR 81814813Slotsmarken 10All other professional, scientific and technical activities n.e.c. · NACE 7499Est. 197729 employees
Revenue 2025
DKK 31,2M
+26% vs 2024
EBITDA margin
25.4%
+82% vs 2024
Equity ratio
52.6%
Financial strength
Net profit 2025
DKK 6,1M
+82% vs 2024
| Revenue | DKK 31,2M | +26% |
| EBITDA | DKK 7,9M | +82% |
| Net profit | DKK 6,1M | +82% |
| Total assets | DKK 12,3M | +78% |
| Equity | DKK 6,5M | +75% |
| Employees | 29 | — |
Legal name
BILLEV PHARMA ApS
CVR number
81814813
Legal form
Anpartsselskab
NACE code
7499 · All other professional, scientific and technical activities n.e.c.
Founded
22. juli 1977
Share capital
DKK 320.000
Employees
29 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-04-30
Financial year
January – December
Signatory rights
Selskabet tegnes af den samlede direktion.
Company purpose
Selskabets formål er at drive famaceutisk-medicinsk- og lignende konsulent- og agenturvirksomhed, samt dermed i forbindelse såtende virksomhed
Address
Slotsmarken 10
Phone
+4547522600
Email
billev@billevpharma.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.956 | 9.417 | 9.724 | 9.747 | — | 14.557 | 17.088 | 17.492 | 21.428 | 25.638 | 30.171 | 29.073 | 24.763 | 31.189 |
| Staff expenses | -0 | -0 | -6.229 | -6.601 | -7.860 | -9.804 | -10.243 | -11.584 | -13.688 | -15.913 | -19.409 | -19.348 | -17.384 | -19.493 |
| EBITDA | 186 | 1.362 | 1.083 | 955 | 2.596 | 2.699 | 4.798 | 3.263 | 4.895 | 7.120 | 7.761 | 6.394 | 4.357 | 7.923 |
| Depreciation & amort. | -0 | -378 | -357 | -106 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 186 | 984 | 726 | 848 | 2.596 | 2.699 | 4.798 | 3.263 | 4.895 | 7.120 | 7.761 | 6.394 | 4.357 | 7.923 |
| Net financials | 18 | 16 | -10 | -9 | -20 | 31 | -7 | -55 | -33 | 0 | -41 | -52 | -15 | -19 |
| Profit before tax | 204 | 1.002 | 717 | 840 | 2.576 | 2.730 | 4.791 | 3.208 | 4.862 | 7.120 | 7.721 | 6.342 | 4.342 | 7.904 |
| Tax | 76 | 274 | 200 | 203 | 568 | 610 | 1.065 | 715 | 1.076 | 1.571 | 1.707 | 1.399 | 963 | 1.760 |
| Net profit | 128 | 728 | 517 | 636 | 2.008 | 2.120 | 3.726 | 2.493 | 3.787 | 5.549 | 6.013 | 4.943 | 3.379 | 6.144 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 4.511 | 4.285 | 5.252 | 3.107 | 4.587 | 4.816 | 6.789 | 5.393 | 8.065 | 9.366 | 10.362 | 8.946 | 6.911 | 12.280 |
| Equity | 2.314 | 2.441 | 1.458 | 956 | 2.328 | 2.440 | 4.046 | 2.813 | 4.107 | 5.869 | 6.333 | 5.263 | 3.699 | 6.464 |
| Long-term debt | 0 | 0 | 273 | 252 | 0 | 0 | 0 | 0 | 624 | 347 | 1.451 | 1.362 | 607 | 260 |
| Short-term debt | 1.974 | 1.702 | 3.461 | 1.888 | 2.222 | 2.346 | 2.698 | 2.506 | 3.263 | 3.051 | 2.461 | 2.234 | 2.532 | 5.495 |
| Total debt | 1.974 | 1.702 | 3.734 | 2.139 | 2.222 | 2.346 | 2.698 | 2.506 | 3.887 | 3.397 | 3.912 | 3.595 | 3.139 | 5.755 |
EBITDA margin
25.4%
This company
15.8%
Market median
+61% vs market
20122025
Equity ratio
52.6%
This company
38.2%
Market median
+38% vs market
20122025
Return on equity
95.0%
This company
18.4%
Market median
+416% vs market
20122025
Net profit margin
19.7%
This company
8.1%
Market median
+143% vs market
20122025
Asset turnover
2.54×
This company
1.12×
Market median
+127% vs market
20122025
Debt / equity
0.90×
This company
0.62×
Market median
+45% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via CVR / Virk · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via CVR / Virk · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via CVR / Virk · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via CVR / Virk · Period 2020-05-01 – 2021-04-30
- Annual report 2020Filed via CVR / Virk · Period 2019-05-01 – 2020-04-30
- Annual report 2019Filed via CVR / Virk · Period 2018-05-01 – 2019-04-30
- Annual report 2018Filed via CVR / Virk · Period 2017-05-01 – 2018-04-30
- Annual report 2017Filed via CVR / Virk · Period 2016-05-01 – 2017-04-30
- Annual report 2016Filed via CVR / Virk · Period 2015-05-01 – 2016-04-30
- Annual report 2015Filed via CVR / Virk · Period 2014-05-01 – 2015-04-30
- Annual report 2014Filed via CVR / Virk · Period 2013-05-01 – 2014-04-30
- Annual report 2013Filed via CVR / Virk · Period 2012-05-01 – 2013-04-30
- Annual report 2012Filed via CVR / Virk · Period 2011-05-01 – 2012-04-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
UL Management | Management | 2015 | — | — |
AW Management | Management | 2015 | — | — |
Pd Management | Management | 1977 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
UL JENSEN HOLDING ApS | Company | 50.0% | 50.0% | 2016 |
VAN ARKENS HOLDING ApS | Company | 50.0% | 50.0% | 2016 |
BILLEV HOLDING ApS | Company | 25.0% | 25.0% | 2011 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
VAN ARKENS HOLDING ApS
BILLEV PHARMA ApS Board members of BILLEV PHARMA ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ulrikke Lynge Jensen | Management | 0 companies |
| Anja Wencke van Arkens | Management | 0 companies |
| Peter de Mayo Billev | Management | 0 companies |